Application value of hemoperfusion combined with hemodialysis in uremia

Objective To investigate the application value of hemoperfusion combined with hemodialysis in uremia and its effect on the prevalence of cardiac valve calcification. Methods A total of 80 patients with uremia from August 2016 to August 2017 were selected and randomly divided into control group and study group, with 40 cases in each group. The control group was treated with hemodialysis, and the study group was treated with hemoperfusion + hemodialysis. All of them were treated for 3 months. The serum inflammatory cytokines [tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), high sensitive C reactive protein (hs-CRP)], and the levels of biochemical indicators [blood phosphorus, blood calcium, beta 2-microglobulin (beta 2-MG)] and the incidence of complications (heart valve calcification, hypotension, pruritus) before treatment and after 3 month of treatment of two groups were statistically recorded. After 6 months of follow-up, the scores of quality of life (SF-36) before and after treatment were counted in the two groups. Results Before treatment, there were no significant differences in the levels of serum TNF-α, IL-6 or hs-CRP between the two groups(P>0.05). After 3 months of treatment, the levels of serum TNF-α, IL-6 and hs-CRP in the two groups were lower than those before the treatment, and those of the study group were lower than those of the control group(P 0.05). After 3 months of treatment, the levels of serum β2-MG, blood phosphorus and blood calcium in the two groups were lower than those before the treatment, and those of the study group were lower than those of the control group(P 0.05). Before treatment, there were no significant differences in the SF-36 scores between the two groups(P>0.05). After 6 months, the SF-36 scores of the two groups were higher than those before treatment, and thsoe of the study group were higher than those of the control group(P<0.05). Conclusions Combination of hemoperfusion and hemodialysis for uremic disease can effectively reduce the levels of serum inflammatory factors and blood phosphorus, calcium and other biochemical indicators, reduce the risk of cardiac valve calcification, and it can effectively improve the quality of life of patients. Key words: Hemoperfusion; Hemodialysis; Uremia; Cardiac valve calcification